Abstract
Antiphospholipid antibodies (aPL) are commonly found in humans after an infection. Its action can promote thrombosis via the activation of endothelial cells, platelets, and neutrophils. This autoantibody is the leading cause of antiphospholipid antibody syndrome (APS), characterized by widespread thrombosis in various vascular beds. COVID-19 also causes acute ischemic stroke (AIS) in the younger demographic, who previously was not considered a population at risk for AIS, which may be related to APS. This narrative review will discuss the role of aPL in COVID-19 patients who experienced AIS during infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
